More importantly, given that immunotherapy relying only on PD-L1 expression levels has not yielded satisfactory results, we predicted and screened potential therapeutic drugs targeting specific populations who have high PD-L1 expression levels, high macrophage infiltration levels, and high inflammatory response activities, which may provide promising therapeutic approaches for HCC PMI patients. This evidence concerns the gene CD274 and hepatocellular carcinoma.